Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial

AIMS: To assess the efficacy and safety of iGlarLixi (the titratable fixed‐ratio combination of insulin glargine 100 U/mL [iGlar] plus lixisenatide [Lixi]), in adults with type 2 diabetes (T2D) with glycated haemoglobin (HbA1c) levels ≥8% (≥64 mmol/mol). MATERIALS AND METHODS: The LixiLan‐O study (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Melanie J., Rosenstock, Julio, Ali, Amar, Russell‐Jones, David, Souhami, Elisabeth, Palmer, Karen, Ji, Chen, Niemoeller, Elisabeth, Skolnik, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293415/
https://www.ncbi.nlm.nih.gov/pubmed/34617398
http://dx.doi.org/10.1111/dom.14543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293415/
https://www.ncbi.nlm.nih.gov/pubmed/34617398
http://dx.doi.org/10.1111/dom.14543

Ejemplares similares